FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2086415911> ?p ?o ?g. }

• W2086415911 endingPage "890" @default.
• W2086415911 startingPage "885" @default.
• W2086415911 abstract "Objective: Protease inhibitors and other antiretroviral drugs have been associated with dyslipidemia, endothelial dysfunction, and increased cardiovascular disease risk. The protease inhibitor atazanavir has an advantageous lipid profile; we studied its effects on arterial function and other metabolic and inflammatory cardiovascular disease risk factors. Design: Prospective, randomized, multinational trial in HIV-infected patients receiving stable protease inhibitor-based therapy with plasma HIV RNA less than 500 copies/ml and fasting low-density lipoprotein cholesterol more than 130 mg/dl, or triglycerides more than 200 mg/dl. Methods: Patients were randomized to continue their current protease inhibitor or switch the protease inhibitor to atazanavir and continue ritonavir if given as a protease inhibitor booster for 24 weeks. Brachial artery flow-mediated dilation, lipoproteins, and inflammatory and metabolic markers were measured at baseline, week 12, and week 24. Median changes within (signed rank test) and between (Wilcoxon test) arms were calculated. Results: Twenty-six patients switched to atazanavir (all continued on ritonavir); 24 remained on their protease inhibitor regimen. Median CD4 cell count was 499 cells/μl, total cholesterol 204 mg/dl, low-density lipoprotein cholesterol 122 mg/dl, and triglycerides 244 mg/dl. There were no significant changes in flow-mediated dilation after 12 and 24 weeks. At 24 weeks, significant changes in the atazanavir vs. continued protease inhibitor group were observed for total cholesterol (−25 vs. +1.5 mg/dl, P = 0.009), triglycerides (−58 vs. +3.5 mg/dl, P = 0.013), and nonhigh-density lipoprotein cholesterol (−27 vs. −0.5 mg/dl, P = 0.014). Conclusion: In dyslipidemic individuals with suppressed HIV RNA on stable therapy, changing the protease inhibitor to atazanavir/ritonavir for 24 weeks improved lipids; however, endothelial function, inflammatory, and metabolic markers did not change." @default.
• W2086415911 created "2016-06-24" @default.
• W2086415911 creator A5009227700 @default.
• W2086415911 creator A5041036157 @default.
• W2086415911 creator A5041994817 @default.
• W2086415911 creator A5049139065 @default.
• W2086415911 creator A5049227770 @default.
• W2086415911 creator A5053198362 @default.
• W2086415911 creator A5054757201 @default.
• W2086415911 creator A5055013057 @default.
• W2086415911 creator A5073329988 @default.
• W2086415911 creator A5083388979 @default.
• W2086415911 date "2010-03-27" @default.
• W2086415911 modified "2023-09-30" @default.
• W2086415911 title "Change to atazanavir/ritonavir treatment improves lipids but not endothelial function in patients on stable antiretroviral therapy" @default.
• W2086415911 cites W138587671 @default.
• W2086415911 cites W1426208733 @default.
• W2086415911 cites W1555489744 @default.
• W2086415911 cites W1767400858 @default.
• W2086415911 cites W1849785625 @default.
• W2086415911 cites W1976641979 @default.
• W2086415911 cites W1979625649 @default.
• W2086415911 cites W1984875752 @default.
• W2086415911 cites W1987260222 @default.
• W2086415911 cites W1992488558 @default.
• W2086415911 cites W2008791277 @default.
• W2086415911 cites W2033049238 @default.
• W2086415911 cites W2060825301 @default.
• W2086415911 cites W2078529164 @default.
• W2086415911 cites W2105343975 @default.
• W2086415911 cites W2106106432 @default.
• W2086415911 cites W2113446450 @default.
• W2086415911 cites W2160234571 @default.
• W2086415911 cites W2316821288 @default.
• W2086415911 doi "https://doi.org/10.1097/qad.0b013e3283352ed5" @default.
• W2086415911 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19952712" @default.
• W2086415911 hasPublicationYear "2010" @default.
• W2086415911 type Work @default.
• W2086415911 sameAs 2086415911 @default.
• W2086415911 citedByCount "47" @default.
• W2086415911 countsByYear W20864159112012 @default.
• W2086415911 countsByYear W20864159112013 @default.
• W2086415911 countsByYear W20864159112014 @default.
• W2086415911 countsByYear W20864159112015 @default.
• W2086415911 countsByYear W20864159112016 @default.
• W2086415911 countsByYear W20864159112017 @default.
• W2086415911 countsByYear W20864159112018 @default.
• W2086415911 countsByYear W20864159112019 @default.
• W2086415911 countsByYear W20864159112020 @default.
• W2086415911 countsByYear W20864159112021 @default.
• W2086415911 countsByYear W20864159112022 @default.
• W2086415911 countsByYear W20864159112023 @default.
• W2086415911 crossrefType "journal-article" @default.
• W2086415911 hasAuthorship W2086415911A5009227700 @default.
• W2086415911 hasAuthorship W2086415911A5041036157 @default.
• W2086415911 hasAuthorship W2086415911A5041994817 @default.
• W2086415911 hasAuthorship W2086415911A5049139065 @default.
• W2086415911 hasAuthorship W2086415911A5049227770 @default.
• W2086415911 hasAuthorship W2086415911A5053198362 @default.
• W2086415911 hasAuthorship W2086415911A5054757201 @default.
• W2086415911 hasAuthorship W2086415911A5055013057 @default.
• W2086415911 hasAuthorship W2086415911A5073329988 @default.
• W2086415911 hasAuthorship W2086415911A5083388979 @default.
• W2086415911 hasConcept C126322002 @default.
• W2086415911 hasConcept C134018914 @default.
• W2086415911 hasConcept C142462285 @default.
• W2086415911 hasConcept C203014093 @default.
• W2086415911 hasConcept C2777182164 @default.
• W2086415911 hasConcept C2778096610 @default.
• W2086415911 hasConcept C2778163477 @default.
• W2086415911 hasConcept C2778414717 @default.
• W2086415911 hasConcept C2778913445 @default.
• W2086415911 hasConcept C2779298103 @default.
• W2086415911 hasConcept C2780072125 @default.
• W2086415911 hasConcept C2781143361 @default.
• W2086415911 hasConcept C2993143319 @default.
• W2086415911 hasConcept C3013748606 @default.
• W2086415911 hasConcept C555293320 @default.
• W2086415911 hasConcept C71924100 @default.
• W2086415911 hasConcept C90924648 @default.
• W2086415911 hasConcept C98274493 @default.
• W2086415911 hasConceptScore W2086415911C126322002 @default.
• W2086415911 hasConceptScore W2086415911C134018914 @default.
• W2086415911 hasConceptScore W2086415911C142462285 @default.
• W2086415911 hasConceptScore W2086415911C203014093 @default.
• W2086415911 hasConceptScore W2086415911C2777182164 @default.
• W2086415911 hasConceptScore W2086415911C2778096610 @default.
• W2086415911 hasConceptScore W2086415911C2778163477 @default.
• W2086415911 hasConceptScore W2086415911C2778414717 @default.
• W2086415911 hasConceptScore W2086415911C2778913445 @default.
• W2086415911 hasConceptScore W2086415911C2779298103 @default.
• W2086415911 hasConceptScore W2086415911C2780072125 @default.
• W2086415911 hasConceptScore W2086415911C2781143361 @default.
• W2086415911 hasConceptScore W2086415911C2993143319 @default.
• W2086415911 hasConceptScore W2086415911C3013748606 @default.
• W2086415911 hasConceptScore W2086415911C555293320 @default.
• W2086415911 hasConceptScore W2086415911C71924100 @default.
• W2086415911 hasConceptScore W2086415911C90924648 @default.

• next